Angion Biomedica analyst ratings
Angion Biomedica analyst ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/18/2022 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 06/30/2022 | — | Oppenheimer | Downgrades | Outperform → Perform | |
| 06/30/2022 | 41.51% | Stifel | $5 → $1.5 | Downgrades | Buy → Hold |
| 05/23/2022 | 2541.51% | HC Wainwright & Co. | $32 → $28 | Maintains | Buy |
| 04/18/2022 | 2918.87% | HC Wainwright & Co. | $50 → $32 | Maintains | Buy |
| 12/10/2021 | 654.72% | Oppenheimer | $15 → $8 | Maintains | Outperform |
| 11/09/2021 | 4616.98% | HC Wainwright & Co. | $100 → $50 | Maintains | Buy |
| 10/27/2021 | 1315.09% | Stifel | $40 → $15 | Maintains | Buy |
| 03/02/2021 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 03/02/2021 | 3484.91% | Oppenheimer | → $38 | Initiates Coverage On | → Outperform |
| 03/02/2021 | 3673.58% | Stifel | → $40 | Initiates Coverage On | → Buy |
| 03/01/2021 | 9333.96% | HC Wainwright & Co. | → $100 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 07/18/2022 | - | HC Wainwright公司 | 評級下調 | 購買→中性 | |
| 2022/06/30 | - | 奧本海默 | 評級下調 | 超越→表現 | |
| 2022/06/30 | 41.51% | Stifel | $5→$1.5 | 評級下調 | 購買→Hold |
| 2022年05月23日 | 2541.51% | HC Wainwright公司 | $32→$28 | 維護 | 買 |
| 04/18/2022 | 2918.87% | HC Wainwright公司 | $50→$32 | 維護 | 買 |
| 2021年12月10日 | 654.72% | 奧本海默 | $15→$8 | 維護 | 跑贏大盤 |
| 11/09/2021 | 4616.98% | HC Wainwright公司 | $100→$50 | 維護 | 買 |
| 10/27/2021 | 1315.09% | Stifel | $40→$15 | 維護 | 買 |
| 03/02/2021 | - | 考恩公司 | 開始承保 | →跑贏大盤 | |
| 03/02/2021 | 3484.91% | 奧本海默 | →$38 | 開始承保 | →跑贏大盤 |
| 03/02/2021 | 3673.58% | Stifel | →$40 | 開始承保 | →購買 |
| 03/01/2021 | 9333.96% | HC Wainwright公司 | →$100 | 開始承保 | →購買 |
Angion Biomedica Questions & Answers
Angion Biomedica問答
The latest price target for Angion Biomedica (NASDAQ: ANGN) was reported by HC Wainwright & Co. on July 18, 2022. The analyst firm set a price target for $0.00 expecting ANGN to fall to within 12 months (a possible -100.00% downside). 8 analyst firms have reported ratings in the last year.
納斯達克(Angion Biomedica)的最新目標價是由HC Wainwright&Co.於2022年7月18日報道的。這家分析公司將目標價定為0.00美元，預計ANGN將在12個月內下跌(跌幅可能為-100.00%)。去年有8家分析公司公佈了評級。
The latest analyst rating for Angion Biomedica (NASDAQ: ANGN) was provided by HC Wainwright & Co., and Angion Biomedica downgraded their neutral rating.
納斯達克的最新分析師評級是由HC Wainwright&Co.提供的，Angion Biomedica下調了其中性評級。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Angion Biomedica, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Angion Biomedica was filed on July 18, 2022 so you should expect the next rating to be made available sometime around July 18, 2023.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Angion Biomedica的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Angion Biomedica的上一次評級是在2022年7月18日提交的，所以你應該預計下一次評級將在2023年7月18日左右的某個時候提供。
While ratings are subjective and will change, the latest Angion Biomedica (ANGN) rating was a downgraded with a price target of $0.00 to $0.00. The current price Angion Biomedica (ANGN) is trading at is $1.06, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Angion Biomedica(ANGN)評級被下調，目標價為0.00美元至0.00美元。Angion Biomedica(ANGN)目前的股價為1.06美元，超出了分析師的預測區間。